Daewoong Pharmaceutical, Sears, and TR to Develop 'Next-Generation Smart Ward Solution'
Integration of Digital Pulmonary Function Testing Device "The Spirokit"
with Smart Bed Monitoring System "Think"
Daewoong Pharmaceutical is partnering with Sears and TR to develop a next-generation smart ward solution that combines smart bed monitoring with digital pulmonary function testing.
On May 28, Daewoong Pharmaceutical announced that it had signed a "Memorandum of Understanding (MOU) for the Expansion of Digital Healthcare Solutions" with Sears and TR at its headquarters in Gangnam-gu, Seoul on May 21.
The core of this collaboration is the integration of Sears' smart bed monitoring system "Think" with TR's digital-based pulmonary function testing device "The Spirokit." The three companies plan to connect bio-signal monitoring data and respiratory test data to develop an integrated smart medical solution for practical use in hospitals, with the aim of commercializing it.
Byungsoo Kim, CEO of TR (left), Changjae Lee, CEO of Daewoong Pharmaceutical, and Youngshin Lee, CEO of Sears, are posing for a commemorative photo. Daewoong Pharmaceutical
View original imageThe Spirokit is a wireless handheld device that analyzes a test subject's breathing patterns in real time and supports the diagnosis of major respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma through a digital-based automatic interpretation function. Thanks to its lightweight and portable design, it can be flexibly used not only in screening centers, but also in wards, mobile testing, and large-scale screening environments. In addition, web- and app-based quality control and calibration functions minimize inter-examiner variance and enable systematic quality management at the institutional level.
Through this agreement, the three companies will jointly pursue research and development as well as demonstration projects to build the next-generation smart ward platform. Daewoong Pharmaceutical will be responsible for promoting and marketing the solution to hospitals and medical institutions, and will support sales activities for its adoption at new hospitals. Sears will conduct joint research and development of medical service solutions based on the integration of Think and The Spirokit, and will further refine the business model through clinical research and demonstration projects. TR will ensure technical stability by integrating The Spirokit and related systems with Think, and will proceed with on-site implementation at hospitals.
Currently, there are ongoing structural issues related to pulmonary function testing in medical settings. Preoperative pulmonary function tests are a key procedure to prevent complications from decreased lung function after anesthesia. However, hospitalized patients with limited mobility must travel to the test room themselves, exposing them to the risk of falls or frequent delays in surgery schedules due to waiting times for tests. Similarly, inpatients with respiratory diseases need to have their pulmonary function changes monitored periodically, but the test room-centered system has made continuous management in the ward difficult.
The integration of Think and The Spirokit addresses these issues. If a physician prescribes a pulmonary function test through Think, the test can be performed immediately at the bedside, reducing the burden of patient movement and test delays. In addition, pulmonary function changes in respiratory inpatients can be checked regularly in the ward, enabling more continuous and precise management.
In particular, when bio-signal data such as electrocardiogram, oxygen saturation, and respiratory rate, which are collected in real time by Think, are integrated and analyzed together with pulmonary function test data using AI, it becomes possible to detect early signs of respiratory abnormalities that are difficult to identify with a single metric and to proactively identify high-risk patients. This is expected to become a next-generation smart ward model that supports rapid response by medical staff.
Kim Byungsu, CEO of TR, said, "There has long been a demand in the field for pulmonary function tests to be conducted at the patient's bedside, outside the testing room. Through this collaboration, even bedridden inpatients with limited mobility will be able to safely undergo pulmonary function tests at their bedside, and we expect to reduce scheduling delays caused by postponed preoperative testing."
Lee Youngshin, CEO of Sears, commented, "This collaboration is an opportunity to realize a digital healthcare model that connects the entire patient lifecycle, going beyond inpatient monitoring to include respiratory disease management, rehabilitation, and even home care. By integrating Think and The Spirokit, we will create a tighter patient management environment."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Changjae, CEO of Daewoong Pharmaceutical, stated, "This agreement is a meaningful attempt to expand the scope of smart wards by combining specialized diagnostic devices with bed monitoring. By integrating Think and The Spirokit, we aim to improve access to pulmonary function tests within wards and create an environment where medical staff can manage patients more efficiently." He added, "Daewoong Pharmaceutical will actively support the rapid dissemination of digital healthcare solutions that have been verified in hospital settings into actual medical environments."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.